MiR-30 Family: A Novel Avenue for Treating Bone and Joint Diseases?

Overview

Journal Int J Med Sci

Specialty General Medicine

Date 2023 Apr 14

PMID 37057210

Authors

Jinming Huang

Yi Li

Siyi Zhu

Liqiong Wang

Lin Yang

Chengqi He

Affiliations

Soon will be listed here.

Abstract

Bone and joint diseases are a group of clinically heterogeneous diseases characterized by various bone strength disorders, bone structural defects and bone mass abnormalities. Common bone diseases include osteoporosis, skeletal dysplasia, and osteosarcoma, and common joint diseases include osteoarthritis, rheumatoid arthritis, and degenerative disc disease. all of them lead to high medical costs. The miR-30 family consists of a total of 5 members: miR-30a, miR-30b, miR-30c, miR-30d and miR-30e. Accumulating evidence has indicated that the miR-30 family may be involved in the occurrence and development of bone and joint diseases. For example, miR-30a is highly expressed in blood samples of osteoporosis patients, miR-30a/b increases in cartilage tissue of osteoarthritis patients, and lower expression of miR-30c is associated with higher malignance and shorter survival time of osteosarcoma. Mechanistically, by targeting crucial transcription factors (RUNX2, SOX9, beclin-1, etc.), the miR-30 family regulates some critical pathways of bone homeostasis (Wnt/β-Catenin, mTOR, PI3K/AKT, etc.). In view of the distinct actions of the miR-30 family on bone metabolism, we hypothesize that the miR-30 family may be a new remedy for the clinical treatment and prevention of some bone and joint diseases.

Citing Articles

Global research trends and hotspots in metabolomics of osteosarcoma: a decade-spanning bibliometric and visualized analysis.

Tu J, Liu T, Li J, Long J, Wang X, Liu W Front Immunol. 2024; 15:1463078.

PMID: 39445018 PMC: 11496093. DOI: 10.3389/fimmu.2024.1463078.

Assessment of the Role of miR-30a-5p on the Proliferation and Apoptosis of Hair Follicle Stem Cells.

Wang Y, Wu W, Wang R, Chen J, Xu X, Li M J Cosmet Dermatol. 2024; 24(1):e16644.

PMID: 39440357 PMC: 11743330. DOI: 10.1111/jocd.16644.

Application of cord blood-derived platelet-rich plasma in the treatment of diseases.

Tang Y, Li Y, Chen H, Huang Y, Huang C, Wei W J Int Med Res. 2024; 52(7):3000605241263729.

PMID: 39068531 PMC: 11287719. DOI: 10.1177/03000605241263729.

The Involvement of microRNAs in Bone Remodeling Signaling Pathways and Their Role in the Development of Osteoporosis.

Jimenez-Ortega R, Ortega-Melendez A, Patino N, Rivera-Paredez B, Hidalgo-Bravo A, Velazquez-Cruz R Biology (Basel). 2024; 13(7).

PMID: 39056698 PMC: 11273958. DOI: 10.3390/biology13070505.

Supragingival Bacterium Oral Infection-Induced Periodontitis and Robust miRNA Expression Kinetics.

Aravindraja C, Jeepipalli S, Duncan W, Vekariya K, Rahaman S, Chan E Int J Mol Sci. 2024; 25(11).

PMID: 38892405 PMC: 11172800. DOI: 10.3390/ijms25116217.

References

John B, Enright A, Aravin A, Tuschl T, Sander C, Marks D . Human MicroRNA targets. PLoS Biol. 2004; 2(11):e363. PMC: 521178. DOI: 10.1371/journal.pbio.0020363. View

Bergamo A, Madalena I, Omori M, Ramazzotto L, Nelson-Filho P, Baratto-Filho F . Estrogen deficiency during puberty affects the expression of microRNA30a and microRNA503 in the mandibular condyle. Ann Anat. 2021; 240:151865. DOI: 10.1016/j.aanat.2021.151865. View

Liu X, Yang B, Zhang Y, Guo X, Yang Q, Liu X . miR-30a-5p inhibits osteogenesis and promotes periodontitis by targeting Runx2. BMC Oral Health. 2021; 21(1):513. PMC: 8504121. DOI: 10.1186/s12903-021-01882-9. View

Dai J, Huang W, Li C, Deng J, Lin S, Luo J . Silencing of long noncoding RNA SBF2-AS1 inhibits proliferation, migration and invasion and contributes to apoptosis in osteosarcoma cells by upregulating microRNA-30a to suppress FOXA1 expression. Cell Cycle. 2019; 18(20):2727-2741. PMC: 6773246. DOI: 10.1080/15384101.2019.1656478. View

Chen F, Wang S, Wei Y, Wu J, Huang G, Chen J . Norcantharidin modulates the miR-30a/Metadherin/AKT signaling axis to suppress proliferation and metastasis of stromal tumor cells in giant cell tumor of bone. Biomed Pharmacother. 2018; 103:1092-1100. DOI: 10.1016/j.biopha.2018.04.100. View

Vasuri F, Ciavarella C, Fittipaldi S, Pini R, Vacirca A, Gargiulo M . Different histological types of active intraplaque calcification underlie alternative miRNA-mRNA axes in carotid atherosclerotic disease. Virchows Arch. 2019; 476(2):307-316. DOI: 10.1007/s00428-019-02659-w. View

Kranjc T, Milojevic M, Kocjan T, Jensterle M, Marc J, Ostanek B . Plasma levels of miR-30d-5p are decreased in regularly exercising postmenopausal women. Menopause. 2019; 27(3):319-325. DOI: 10.1097/GME.0000000000001454. View

Gradus B, Alon I, Hornstein E . miRNAs control tracheal chondrocyte differentiation. Dev Biol. 2011; 360(1):58-65. DOI: 10.1016/j.ydbio.2011.09.002. View

Li L, Yang C, Liu X, Yang S, Ye S, Jia J . Elevated expression of microRNA-30b in osteoarthritis and its role in ERG regulation of chondrocyte. Biomed Pharmacother. 2015; 76:94-9. DOI: 10.1016/j.biopha.2015.10.014. View

10.

Gu Z, Hou Z, Zheng L, Wang X, Wu L, Zhang C . LncRNA DICER1-AS1 promotes the proliferation, invasion and autophagy of osteosarcoma cells via miR-30b/ATG5. Biomed Pharmacother. 2018; 104:110-118. DOI: 10.1016/j.biopha.2018.04.193. View

11.

Chen Z, Jin T, Lu Y . AntimiR-30b Inhibits TNF-α Mediated Apoptosis and Attenuated Cartilage Degradation through Enhancing Autophagy. Cell Physiol Biochem. 2016; 40(5):883-894. DOI: 10.1159/000453147. View

12.

Xu H, Zhang J, Shi X, Li X, Zheng C . NF-κB inducible miR-30b-5p aggravates joint pain and loss of articular cartilage via targeting SIRT1-FoxO3a-mediated NLRP3 inflammasome. Aging (Albany NY). 2021; 13(16):20774-20792. PMC: 8436920. DOI: 10.18632/aging.203466. View

13.

Zaragosi L, Wdziekonski B, Le Brigand K, Villageois P, Mari B, Waldmann R . Small RNA sequencing reveals miR-642a-3p as a novel adipocyte-specific microRNA and miR-30 as a key regulator of human adipogenesis. Genome Biol. 2011; 12(7):R64. PMC: 3218826. DOI: 10.1186/gb-2011-12-7-r64. View

14.

Ayers C, Kansagara D, Lazur B, Fu R, Kwon A, Harrod C . Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians. Ann Intern Med. 2023; 176(2):182-195. DOI: 10.7326/M22-0684. View

15.

Lu N, Lin T, Wang L, Qi M, Liu Z, Dong H . Association of SOX4 regulated by tumor suppressor miR-30a with poor prognosis in low-grade chondrosarcoma. Tumour Biol. 2015; 36(5):3843-52. DOI: 10.1007/s13277-014-3026-2. View

16.

Othman A, Winogradzki M, Lee L, Tandon M, Blank A, Pratap J . Bone Metastatic Breast Cancer: Advances in Cell Signaling and Autophagy Related Mechanisms. Cancers (Basel). 2021; 13(17). PMC: 8431094. DOI: 10.3390/cancers13174310. View

17.

Zhang R, Weng Y, Li B, Jiang Y, Yan S, He F . BMP9-induced osteogenic differentiation is partially inhibited by miR-30a in the mesenchymal stem cell line C3H10T1/2. J Mol Histol. 2015; 46(4-5):399-407. DOI: 10.1007/s10735-015-9628-1. View

18.

Tian Y, Guo R, Shi B, Chen L, Yang L, Fu Q . MicroRNA-30a promotes chondrogenic differentiation of mesenchymal stem cells through inhibiting Delta-like 4 expression. Life Sci. 2016; 148:220-8. DOI: 10.1016/j.lfs.2016.02.031. View

19.

Wu Z, Huang K, Liu K, Wang G, Sun Q . DGCR5 induces osteogenic differentiation by up-regulating Runx2 through miR-30d-5p. Biochem Biophys Res Commun. 2018; 505(2):426-431. DOI: 10.1016/j.bbrc.2018.09.033. View

20.

Zhu B, Chen H, Zhang X, Pan Y, Jing R, Shen L . Serum miR-30d as a novel biomarker for multiple myeloma and its antitumor role in U266 cells through the targeting of the MTDH/PI3K/Akt signaling pathway. Int J Oncol. 2018; 53(5):2131-2144. DOI: 10.3892/ijo.2018.4532. View